Fundz
Real-time · AI · Cross-signal

TRex Bio just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on TRex Bio, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

TRexBio raises $50 million to advance its immunology pipeline, led by investors including Janus Henderson and Balyasny Asset Management.

PRIVATEJan 27, 2026•4 months ago

Amount Raised

$50 Million

South San FranciscoBiotechnologyHealth CareTherapeutics

Investors

Sv Health InvestorsPolaris PartnersPfizer VenturesJohnson & Johnson Innovation – Jjdc, Inc.Eli Lilly And CompanyDelos CapitalAvego Bio Science CapitalAlexandria Venture InvestmentsAffinity Asset AdvisorsBalyasny Asset Management L.P.Janus Henderson Investors

Description

TRex Bio, Inc. announced the closing of an oversubscribed $50 million financing round involving both new and existing investors. The funds will support TRexBio's clinical-stage pipeline of Treg therapeutics, including TRB-061. CEO Johnston Erwin expressed gratitude for the support from healthcare investors

Company Information

Company

TRex Bio

Location

South San Francisco, California, United States

About

TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.

Predictive Intelligence
Strategic

ML-powered predictions for TRex Bio's next move

Learn about Strategic plan

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies.

Watching TRex Bio? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan